Aix-Marseille Univ, APHM, Hôpital Timone Enfants, Pneumo-pédiatrie, Centre de Ressources et de Compétences en Mucoviscidose, Marseille, France.
Aix-Marseille Univ, INSERM UMR 1067, CNRS UMR 7333, Marseille, France.
Allergy. 2017 Nov;72(11):1632-1642. doi: 10.1111/all.13204. Epub 2017 Jun 9.
A wide spectrum of pathological conditions may result from the interaction of Aspergillus fumigatus and the immune system of its human host. Allergic bronchopulmonary aspergillosis is one of the most severe A. fumigatus-related diseases due to possible evolution toward pleuropulmonary fibrosis and respiratory failure. Allergic bronchopulmonary aspergillosis occurs almost exclusively in cystic fibrosis or asthmatic patients. An estimated 8%-10% of patients with cystic fibrosis experience this condition. The diagnosis of allergic bronchopulmonary aspergillosis relies on criteria first established in 1977. Progress in the understanding of host-pathogen interactions in A. fumigatus and patients with cystic fibrosis and the ongoing validation of novel laboratory tools concur to update and improve the diagnosis of allergic bronchopulmonary aspergillosis.
烟曲霉与人类宿主的免疫系统相互作用可能导致广泛的病理状况。过敏性支气管肺曲霉病是最严重的烟曲霉相关疾病之一,因为它可能发展为肺纤维化和呼吸衰竭。过敏性支气管肺曲霉病几乎仅发生于囊性纤维化或哮喘患者。估计有 8%-10%的囊性纤维化患者会出现这种情况。过敏性支气管肺曲霉病的诊断依赖于 1977 年首次确立的标准。对烟曲霉宿主-病原体相互作用以及囊性纤维化患者的认识的不断深入,以及新型实验室工具的持续验证,有助于更新和改进过敏性支气管肺曲霉病的诊断。